Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

New Report: More Than 50 Medicines and Vaccines in Development for HIV Infection, Treatment and Prevention

Washington, DC, June 30, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) reports that America’s biopharmaceutical companies are continuing the fight to conquer the human immunodeficiency virus (HIV), which can develop into acquired immune deficiency syndrome (AIDS).

According to a new report released on June 27 by PhRMA in partnership with The AIDS Institute, 52 medicines and vaccines are currently in development to help treat and prevent the infection.

Among the 52 medicines in development for HIV, there are 32 antiretrovirals and antivirals, 16 vaccines and four cell therapies, including a potential first-in-class medicine intended to prevent HIV from attaching to new cells and breaking through the cell membrane.

Over the past three decades, continued biopharmaceutical innovation in HIV/AIDS treatment — from the discovery of anti-retroviral therapy (ART) in the mid-1990’s to the introduction of medicines to prevent the transmission of HIV, called pre-exposure prophylaxis (PrEP) — has revolutionized the outlook and improved the quality of life for the 1.1 million patients in the United States with HIV.

Commenting on the report, PhRMA President and CEO Stephen J. Ubl said, “Thanks to the hard work and dedication of countless individuals — from biopharmaceutical researchers, to those patients enrolled in clinical trials — we have seen an 88 percent decline in the HIV/AIDS death rate since the 1990s1 and an estimated 862,000 premature HIV/AIDS deaths have been prevented in the United States2.”

“While we have made great progress,” Ubl said, “there is more to be done, which is why the 52 medicines and vaccines in development offer tremendous hope and inspiration that an AIDS-free generation may one day be in reach.”

Carl Schmid, Deputy Executive Director of The AIDS Institute, said, “Scientific innovations like ART medicines have dramatically altered the treatment paradigm for people living with HIV/AIDS, who can now live longer, healthier lives.  And, now we have medications like PrEP, that actually prevent HIV transmission.”

Schmid added, “While we are excited for the robust pipeline in the treatment and prevention of HIV/AIDS, and patients’ lives continue to improve, it’s still crucial that we increase awareness and education about the virus, stress the importance of getting tested and seek to end the stigma associated with HIV/AIDS.”

As part of the GOBOLDLY campaign, PhRMA also released a new ad on June 27, in its Together series showcasing the resilience of researchers and patients in the fight against HIV/AIDS.

The full “Medicines in Development for HIV/AIDS” report can be downloaded here.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.

Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.